Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature.

Pircher A, Schäfer G, Eigentler A, Pichler R, Puhr M, Steiner E, Horninger W, Gunsilius E, Klocker H, Heidegger I.

Int J Med Sci. 2019 Jan 1;16(1):115-124. doi: 10.7150/ijms.28735. eCollection 2019.

2.

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.

Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, Guggenberger F, Santer FR, Marques RB, van Weerden WM, Claessens F, Erb HHH, Culig Z.

Mol Cancer Ther. 2018 Dec;17(12):2722-2731. doi: 10.1158/1535-7163.MCT-18-0508. Epub 2018 Sep 25.

PMID:
30254184
3.

Antidiabetic drugs influence molecular mechanisms in prostate cancer.

Pircher A, Zieher M, Eigentler A, Pichler R, Schäfer G, Fritz J, Puhr M, Steiner E, Horninger W, Klocker H, Heidegger I.

Cancer Biol Ther. 2018;19(12):1153-1161. doi: 10.1080/15384047.2018.1491490. Epub 2018 Aug 1.

4.

Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.

Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Puhr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, Shariat SF, Kramer G.

BJU Int. 2018 Oct;122(4):695-704. doi: 10.1111/bju.14415. Epub 2018 Jun 20.

5.

Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated protumorigenic interactions.

Sampson N, Brunner E, Weber A, Puhr M, Schäfer G, Szyndralewiez C, Klocker H.

Int J Cancer. 2018 Jul 15;143(2):383-395. doi: 10.1002/ijc.31316. Epub 2018 Mar 1.

6.

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.

Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, Culig Z, Van der Pluijm G, Klocker H.

Clin Cancer Res. 2018 Feb 15;24(4):927-938. doi: 10.1158/1078-0432.CCR-17-0989. Epub 2017 Nov 20.

7.

Calcineurin inhibitor-induced complement system activation via ERK1/2 signalling is inhibited by SOCS-3 in human renal tubule cells.

Loeschenberger B, Niess L, Würzner R, Schwelberger H, Eder IE, Puhr M, Guenther J, Troppmair J, Rudnicki M, Neuwirt H.

Eur J Immunol. 2018 Feb;48(2):330-343. doi: 10.1002/eji.201747135. Epub 2017 Dec 11.

8.

Inflammation, Microbiota, and Prostate Cancer.

Puhr M, De Marzo A, Isaacs W, Lucia MS, Sfanos K, Yegnasubramanian S, Culig Z.

Eur Urol Focus. 2016 Oct;2(4):374-382. doi: 10.1016/j.euf.2016.08.010. Epub 2016 Aug 28. Review.

PMID:
28723469
9.

Numerical Study of Nonperturbative Corrections to the Chiral Separation Effect in Quenched Finite-Density QCD.

Puhr M, Buividovich PV.

Phys Rev Lett. 2017 May 12;118(19):192003. doi: 10.1103/PhysRevLett.118.192003. Epub 2017 May 10.

PMID:
28548526
10.

Interleukin-6 and prostate cancer: Current developments and unsolved questions.

Culig Z, Puhr M.

Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):25-30. doi: 10.1016/j.mce.2017.03.012. Epub 2017 Mar 16. Review.

PMID:
28315704
11.

The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.

Hanrahan K, O'Neill A, Prencipe M, Bugler J, Murphy L, Fabre A, Puhr M, Culig Z, Murphy K, Watson RW.

Mol Oncol. 2017 Mar;11(3):251-265. doi: 10.1002/1878-0261.12030. Epub 2017 Jan 30.

12.

Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells.

Ippolito L, Marini A, Cavallini L, Morandi A, Pietrovito L, Pintus G, Giannoni E, Schrader T, Puhr M, Chiarugi P, Taddei ML.

Oncotarget. 2016 Sep 20;7(38):61890-61904. doi: 10.18632/oncotarget.11301.

13.

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.

Hoefer J, Akbor M, Handle F, Ofer P, Puhr M, Parson W, Culig Z, Klocker H, Heidegger I.

Oncotarget. 2016 Sep 13;7(37):59781-59794. doi: 10.18632/oncotarget.10926.

14.

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.

Kroon J, Puhr M, Buijs JT, van der Horst G, Hemmer DM, Marijt KA, Hwang MS, Masood M, Grimm S, Storm G, Metselaar JM, Meijer OC, Culig Z, van der Pluijm G.

Endocr Relat Cancer. 2016 Jan;23(1):35-45. doi: 10.1530/ERC-15-0343. Epub 2015 Oct 19.

15.

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.

Puhr M, Hoefer J, Eigentler A, Dietrich D, van Leenders G, Uhl B, Hoogland M, Handle F, Schlick B, Neuwirt H, Sailer V, Kristiansen G, Klocker H, Culig Z.

Oncogene. 2016 May 5;35(18):2322-32. doi: 10.1038/onc.2015.292. Epub 2015 Aug 10.

16.

miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.

Pasqualini L, Bu H, Puhr M, Narisu N, Rainer J, Schlick B, Schäfer G, Angelova M, Trajanoski Z, Börno ST, Schweiger MR, Fuchsberger C, Klocker H.

Mol Endocrinol. 2015 Jul;29(7):1037-54. doi: 10.1210/me.2014-1358. Epub 2015 Jun 8.

17.

The Use of Transitional Care Models in Patients With Stroke.

Puhr MI, Thompson HJ.

J Neurosci Nurs. 2015 Aug;47(4):223-34. doi: 10.1097/JNN.0000000000000143. Review.

PMID:
25906245
18.

ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.

Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, Lübbert M, Puhr M, Culig Z, Wellner U, Keck T, Bronsert P, Küsters S, Hopt UT, Stemmler MP, Brabletz T.

EMBO Mol Med. 2015 Jun;7(6):831-47. doi: 10.15252/emmm.201404396.

19.

Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivo.

Neuwirt H, Wabnig E, Feistritzer C, Eder IE, Salvador C, Puhr M, Culig Z, Massoner P, Tiefenthaler M, Steurer M, Konwalinka G.

PLoS One. 2015 Feb 13;10(2):e0117806. doi: 10.1371/journal.pone.0117806. eCollection 2015.

20.

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.

Puhr M, Hoefer J, Neuwirt H, Eder IE, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z.

Oncotarget. 2014 Dec 15;5(23):12043-56.

21.

EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205.

Massoner P, Thomm T, Mack B, Untergasser G, Martowicz A, Bobowski K, Klocker H, Gires O, Puhr M.

Br J Cancer. 2014 Aug 26;111(5):955-64. doi: 10.1038/bjc.2014.366. Epub 2014 Jul 3.

22.

SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.

Hoefer J, Kern J, Ofer P, Eder IE, Schäfer G, Dietrich D, Kristiansen G, Geley S, Rainer J, Gunsilius E, Klocker H, Culig Z, Puhr M.

Endocr Relat Cancer. 2014 Jan 30;21(2):175-87. doi: 10.1530/ERC-13-0446. Print 2014 Apr.

23.

Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo.

Eder IE, Egger M, Neuwirt H, Seifarth C, Maddalo D, Desiniotis A, Schäfer G, Puhr M, Bektic J, Cato AC, Klocker H.

Int J Mol Sci. 2013 Jun 4;14(6):11942-62. doi: 10.3390/ijms140611942.

24.

In vitro model systems to study androgen receptor signaling in prostate cancer.

Sampson N, Neuwirt H, Puhr M, Klocker H, Eder IE.

Endocr Relat Cancer. 2013 Mar 26;20(2):R49-64. doi: 10.1530/ERC-12-0401. Print 2013 Apr. Review.

PMID:
23447570
25.

SOCS-3 is downregulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/3 independent manner.

Neuwirt H, Eder IE, Puhr M, Rudnicki M.

Lab Invest. 2013 Jan;93(1):123-34. doi: 10.1038/labinvest.2012.154. Epub 2012 Oct 29.

26.

Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.

Puhr M, Hoefer J, Schäfer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, Culig Z.

Am J Pathol. 2012 Dec;181(6):2188-201. doi: 10.1016/j.ajpath.2012.08.011. Epub 2012 Oct 3.

27.

PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21.

Hoefer J, Schäfer G, Klocker H, Erb HH, Mills IG, Hengst L, Puhr M, Culig Z.

Am J Pathol. 2012 May;180(5):2097-107. doi: 10.1016/j.ajpath.2012.01.026. Epub 2012 Mar 23.

28.

Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.

Culig Z, Puhr M.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):52-8. doi: 10.1016/j.mce.2011.05.033. Epub 2011 Jun 1. Review.

29.

SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.

Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A, Culig Z.

Endocr Relat Cancer. 2010 May 18;17(2):525-38. doi: 10.1677/ERC-10-0007. Print 2010 Jun.

PMID:
20335309
30.

Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo.

Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, Dasgupta A, Hyslop T, Bubendorf L, Alanen K, Mirtti T, Nevalainen MT.

Endocr Relat Cancer. 2010 May 18;17(2):481-93. doi: 10.1677/ERC-09-0328. Print 2010 Jun.

31.

Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.

Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L, Culig Z.

Cancer Res. 2009 Sep 15;69(18):7375-84. doi: 10.1158/0008-5472.CAN-09-0806. Epub 2009 Sep 8.

32.

[Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion].

Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z.

Aktuelle Urol. 2009 Aug;40(4):231-4. doi: 10.1055/s-0028-1098887. Epub 2009 Jul 24. German.

PMID:
19634073
33.

Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.

Neuwirt H, Puhr M, Santer FR, Susani M, Doppler W, Marcias G, Rauch V, Brugger M, Hobisch A, Kenner L, Culig Z.

Am J Pathol. 2009 May;174(5):1921-30. doi: 10.2353/ajpath.2009.080751. Epub 2009 Mar 26.

34.

Oligomeric proanthocyanidin complexes (OPC) exert anti-proliferative and pro-apoptotic effects on prostate cancer cells.

Neuwirt H, Arias MC, Puhr M, Hobisch A, Culig Z.

Prostate. 2008 Nov 1;68(15):1647-54. doi: 10.1002/pros.20829.

PMID:
18663730
35.

Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion.

Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z.

Endocr Relat Cancer. 2007 Dec;14(4):1007-19. Erratum in: Endocr Relat Cancer. 2008 Mar;15(1):366.

PMID:
18045952
36.

Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer.

Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z.

Am J Pathol. 2006 Dec;169(6):2199-208.

Supplemental Content

Support Center